As of 2022, in nearly every country in Europe, over half of adults were classed as overweight or obese. The highest rate was recorded in Romania with 67 percent of adults self-reporting as overweight or obese. In both Croatia and the United Kingdom, around 64 percent of adults had a BMI of over 25. Europe one of the worst affected regions Europe had the second-highest number of obese adults across the WHO regions, only behind the region of the Americas. Over 191 million adults aged 20 years were classed as obese in Europe in 2020. The number of obese adults in Europe was forecast to grow to 263 million by 2035. Problems also with childhood obesity In 2020, 89 million children in Europe were overweight, the highest across all continents. It was forecast with current trends that, by 2035, 125 million children would be overweight. A further 70 million children across the continent were classed as obese. Children that are overweight or obese are at a higher risk of developing numerous health conditions, such as type 2 diabetes, asthma, and high blood pressure.

By 2025, the prevalence of obese men in Hungary was projected to be at 36 percent, this would be the highest obesity prevalence in men across all countries in the EU and the United Kingdom. Malta with 35.9 percent was forecast to have the second highest prevalence of obese men in Europe, followed by the United Kingdom at 35.4 percent.

As of 2021, approximately 69 percent of men and 59 percent of women in the United Kingdom considered themselves overweight or obese. Across the European countries featured, overweight and obesity was more prevalent among males.

By 2025, the prevalence of obese women in the United Kingdom is projected to be at 36 percent, this would be the highest obesity prevalence in women compared to EU countries. Ireland with 33.4 percent was forecast to have the second highest prevalence of obese women in Europe, followed by Malta at 32 percent.

This statistical report presents a range of information on obesity, physical activity and diet, drawn together from a variety of sources.

The topics covered include:

• Overweight and obesity prevalence among adults and children

• Physical activity levels among adults and children

• Trends in purchases and consumption of food and drink and energy intake

• Health outcomes of being overweight or obese.

This report contains seven chapters which consist of the following:

• Chapter 1: Introduction; this summarises government policies, targets and outcome indicators in this area, as well as providing sources of further information and links to relevant documents.

• Chapters 2 to 6 cover obesity, physical activity and diet and provides an overview of the key findings from these sources, whilst maintaining useful links to each section of these reports.

• Chapter 7: Health Outcomes; presents a range of information about the health outcomes of being obese or overweight which includes information on health risks, hospital admissions and prescription drugs used for treatment of obesity.

• Figures presented in this report have been obtained from a number of sources and presented in a user-friendly format. Some of the data contained in the chapter have been published previously by the Health and Social Care Information Centre (HSCIC). Previously unpublished figures on obesity-related Finished Hospital Episodes and Finished Consultant Episodes for 2012-13 are presented using data from the HSCIC's Hospital Episode Statistics as well as data from the Prescribing Unit at the HSCIC on prescription items dispensed for treatment of obesity.

By 2030, Malta, Hungary, and the United Kingdom were projected to have the highest prevalence of obesity in their populations among men in Europe. Across the whole of Europe, approximately 30 percent of men were forecast to be classified as obese in 2030.

The spreadsheet contains regional level obesity trend data from the the HSE, BMI data from Understanding Society, and adjusted prevalence of underweight, healthy weight, overweight, and obesity by local authority from the Active People Survey.

Understanding Society data shows the percentage of the population aged 10 and over by their Body Mass Index Classification, covering underweight, normal weight, overweight, and three classes of obesity.

Questions on self-reported height and weight were added to the Sport England Active People Survey (APS) in January 2012 to provide data for monitoring excess weight (overweight including obesity, BMI ≥25kg/m2) in adults (age 16 and over) at local authority level for the Public Health Outcomes Framework (PHOF).

Health Survey for England (HSE) results at a national level are available on the NHS Information Centre website.

Other NHS indicators on obesity are available for Strategic Health Authorities (SHA).

Relevant links: http://discover.ukdataservice.ac.uk/series/?sn=2000053

http://www.noo.org.uk/visualisation/adult_obesity

Snapshot img

Weight Management Market Size 2024-2028

The weight management market size is forecast to increase by USD 103.8 billion at a CAGR of 10.87% between 2023 and 2028.

The market is witnessing significant growth due to rising obesity rates, particularly in developed and developing economies. The increasing prevalence of sedentary lifestyles, coupled with the influence of social media platforms promoting unhealthy food choices, is fueling this trend. The fast-food industry's continuous expansion and the availability of convenient yet calorie-dense options further exacerbate the issue. Key health concerns, such as cardiovascular diseases, diabetes, hormonal problems, and certain cancers, are associated with obesity. As a result, consumers are seeking effective solutions, leading to a rise in demand for diet meals, beverages, and supplements. This trend is expected to continue, as chronic diseases linked to obesity pose a significant threat to public health. The market is also witnessing innovative marketing strategies and personalized approaches to cater to the diverse needs of consumers. Despite these opportunities, challenges remain, including regulatory hurdles and consumer skepticism towards weight loss solutions.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market encompasses a range of products and services aimed at helping individuals maintain a healthy body weight and improve overall wellness. Obesity, driven by sedentary lifestyles and unhealthy dietary choices, remains a significant global health concern, fueling market growth. Chronic diseases, such as diabetes, hypertension, orthopedic diseases, and cardiovascular diseases, are often associated with obesity and create a strong demand for solutions. 
Additionally, hormonal problems and childhood obesity contribute to market expansion. Preventive health measures, including healthy eating habits, daily physical activities, and services, are increasingly popular. Social media plays a role in promoting weight loss trends, from bariatric surgeries to protein powders and fitness programs. The young population and the Gen X and baby boomer generations are key demographics, as they seek to maintain a healthy weight and address age-related health concerns.

How is this Weight Management Industry segmented and which is the largest segment?

The report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  Diet
  Equipment
  Services


Distribution Channel

  Offline
  Online


Geography

  North America

    US


  Asia

    China
    Japan


  Europe

    Germany
    UK


  Rest of World (ROW)

By Type Insights

The diet segment is estimated to witness significant growth during the forecast period.

The market is driven by the increasing prevalence of obesity and related health conditions, including hypertension, diabetes, and orthopedic diseases. Sedentary lifestyles and the consumption of junk food and fast-food contribute to obesity, affecting over one-third of the global population. Obesity can lead to chronic diseases, such as cardiovascular diseases and certain types of cancer. The market includes various segments, such as diet meals, beverages and supplements, exercise, surgical procedures, and services. Digitalization has led to the growth of online sales, ready-to-drink beverages, bars, gels, and powders. Lifestyle changes, including healthy eating habits and daily physical activities, are essential for maintaining a healthy body weight.

Weight management programs and innovative weight-management products, such as functional beverages, functional food, and dietary supplements, offer prevention and consultation services. The market is expected to grow due to the increasing awareness of weight-related health issues and the desire for a healthy immune system among the young population and Gen X and baby boomer generations.

Get a glance at the market report of the share of various segments Request Free Sample

The diet segment was valued at USD 84.90 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

Asia is estimated to contribute 36% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market size of various regions, Request Free Sample

The market in North America is currently the largest global segment, driven by increasing consumer focus on healthier lifestyles and obesity concerns. With over 35% of American adults classified as obese in 2022, according to the Centers for Disease Control and Prevention (CDC), the US market dominates th

In 2022, over 33 percent of both men and women in the United States reported themselves as obese (BMI over 30), making it the country with the highest percentage of obese adults on this list. Other selected countries on the list with a high prevalence of obesity among adults included the United Kingdom and Australia. Obesity groups in the United States In 2022, Black adults had the highest overweight and obesity rates of any race or ethnicity in the United States. Asians and Native Hawaiians or Pacific Islanders had the lowest rates by far, with roughly 14 percent. In 2021, about 30 percent of people aged 65 and older were obese in the United States. This estimate has been steadily increasing since 2013 when roughly 27 percent of elderly Americans were obese. Leading health problems worldwide Obesity was considered one of 2023’s biggest health problems: 25 percent of adults worldwide stated that obesity was the biggest health issue for people within their country. Around 44 percent of adults stated that mental health was the most significant problem facing their country that year.

Snapshot img

Anti-Obesity Drugs Market Size 2025-2029

The anti-obesity drugs market size is forecast to increase by USD 22.91 billion at a CAGR of 15.7% between 2024 and 2029.

The market is experiencing significant growth due to several key factors. The rising obesity population, particularly in North America, is a major driver for this market. Additionally, research and development efforts are focused on creating drugs that can effectively manage both obesity and type 2 diabetes mellitus. This dual-action approach is gaining popularity as many obese individuals are also at risk for developing type 2 diabetes. Furthermore, the availability of telemedicine services and anti-obesity devices is making weight management more accessible and convenient for individuals. These trends are expected to continue fueling the growth of the market In the coming years. The use of anti-obesity drugs can help regulate insulin production and manage weight by reducing appetite and increasing metabolism. These drugs can have a positive impact on overall health and well-being, making them an essential tool In the fight against obesity and related health conditions.

What will be the Size of the Anti-Obesity Drugs Market During the Forecast Period?

Request Free Sample

The market encompasses a range of medicines designed to assist individuals struggling with weight management, targeting conditions such as obesity and overweight. These conditions are often linked to chronic diseases, including insulin resistance, glucose intolerance, hypertension, sleep apnea, diabetes mellitus, arthritis, and various lifestyle-related illnesses. The prevalence of obesity and overweight continues to rise globally, driven by energy imbalance, with calories consumed exceeding calories expended. Factors contributing to this imbalance include appetite stimulation, metabolic disorders, and fat absorption. The market for anti-obesity drugs is expected to grow significantly due to the increasing burden of obesity and its associated health complications.
This trend is driven by the growing awareness of the health risks associated with obesity and the desire for effective weight loss solutions. The market caters to both adults and children and adolescents, addressing the rising prevalence of obesity across all age groups. The market's growth is further fueled by the increasing incidence of lifestyle-related factors, such as stress, smoking, and drinking, which contribute to weight gain.

How is this Anti-Obesity Drugs Industry segmented and which is the largest segment?

The anti-obesity drugs industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Class III
  Class II anti-obesity drugs
  Class I anti-obesity drugs


Drug Class

  Peripherally acting drugs
  Centrally acting drugs


Distribution Channel

  Hospital pharmacies
  Retail pharmacies
  Drug stores
  E-commerce


Route Of Administration

  Oral route
  Subcutaneous route


Geography

  North America

    Canada
    Mexico
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    Japan


  Rest of World (ROW)

By Type Insights

The class III segment is estimated to witness significant growth during the forecast period. The Class III segment dominates The market due to its focus on addressing severe obesity cases. This segment accounts for a significant market share and is expected to continue its leadership during the forecast period. The rise in research and development initiatives by pharmaceutical companies for novel anti-obesity drugs contributes to market expansion. However, it's important to note that pharmacotherapy for obesity can only achieve a certain reduction in Body Mass Index (BMI). Consequently, the Class III anti-obesity drugs segment may witness a decline during the forecast period as patients may require additional measures for sustained weight loss.
Obesity is a chronic condition with a global prevalence that fuels the demand for weight-loss medicines. These medicines target various mechanisms such as appetite suppression, metabolism enhancement, and fat absorption inhibition. Prevalent conditions associated with obesity include cardiovascular diseases, cancers, type-2 diabetes, and sleep apnea. The market caters to various distribution channels, including retail pharmacies, online pharmacies, and hospital pharmacies. Anti-obesity drugs can be administered through oral and subcutaneous routes.

Get a glance at the market report of share of various segments Request Free Sample

The class III segment was valued at USD 6.85 billion in 2019 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 71% to the growth o

Background: Obesity is a risk factor for many chronic diseases and the prevalence is increasing worldwide. Research suggests that sedentary behaviour (sitting) may be related to obesity. Aim: To examine the association between sitting time and obesity, while controlling for physical activity, in a large international sample. Subjects and methods: In total, 5338 adults from the UK, USA, Germany, Spain, Italy, France, Portugal, Austria and Switzerland self-reported their total daily sitting time, physical activity, age, height and weight. BMI (kg/m2), total physical activity (MET-minutes/week) and sitting time (hours/day) were derived. Participants were grouped into quartiles based on their daily sitting time (8 hours/day) and logistic regression models explored the odds of being obese vs normal weight for each sitting time quartile. Results: Participants in the highest sitting time quartile (≥8 hours/day) had 62% higher odds of obesity compared to participants in the lowest quartile (

The European Weight Loss Management market is segmented by Type (Food and Beverage and Supplements), Distribution Channel (Supermarkets/Hypermarkets, Pharmacies, Specialty Stores, Online Retail Stores, and Other Distribution Channels), and Geography (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe). The report offers the market size in value terms in USD for all the abovementioned segments.

The European weight management supplement market, valued at approximately €[Estimate based on CAGR and Market size XX; Let's assume XX is 1000 for calculation. A market size of €1000 million in a base year with 7.68% CAGR suggests significant growth. Using a simple calculation assuming the given value is for 2024, the 2025 market size would be approximately €1076.8 million] million in 2025, is projected to experience robust growth throughout the forecast period (2025-2033). This expansion is fueled by several key drivers, including rising obesity rates across Europe, increased health consciousness among consumers, and the growing popularity of convenient and effective weight management solutions. The market's segmentation highlights the diverse product offerings, with meal replacements (bars, ready-to-drink products, soups) and slimming teas dominating the food and beverage segment, while capsules/softgels, powders, and tablets lead the supplements category. Distribution channels are varied, with supermarkets/hypermarkets, pharmacies, and online retail stores playing significant roles in reaching consumers. Leading players such as Amway Corp, Herbalife Nutrition, and Glanbia PLC are actively shaping the market through product innovation, strategic partnerships, and targeted marketing campaigns. However, the market also faces challenges. Regulatory scrutiny surrounding supplement efficacy and safety claims, coupled with consumer concerns about potential side effects, acts as a restraint on market growth. Furthermore, the increasing availability of alternative weight management strategies, such as lifestyle modifications and bariatric surgery, presents competitive pressure. Despite these restraints, the continued rise in health concerns and the convenience factor associated with supplements are expected to propel sustained market expansion in the coming years, particularly in regions such as Germany, the United Kingdom, and France, where health consciousness is relatively high and disposable incomes support spending on premium wellness products. The market's projected CAGR of 7.68% indicates a significant opportunity for growth and expansion for both established players and emerging brands. Recent developments include: June 2023: Rapid Nutrition PLC announced the release of its new look and brand identity for the SystemLS weight loss products. The company also claims that it unveiled the new brand identity for the flagship SystemLS Weight Loss Brand as the product continues international expansion., April 2023: Nexira announced the launch of its holistic approach to weight management and introduced two new products, which include products for microbiome modulation called VinOgrape Plus and for appetite control, namely Carolean., March 2023: Novo Nordisk's announced its plans to launch its popular weight loss drug Wegovy in the United Kingdom. The company claims that the UK Medicines and Health Products Regulations Agency approved Wegovy in September 2021 to treat people with a BMI as low as 27., February 2023: Nestlé announced its plans to introduce and sample brand-new product offerings at the Natural Products Expo West 2023 Trade Show. The brand-new offerings include NEW Solgar Probiotic Line. The company claims that Solgar is designed to meet consumers' needs with benefits beyond digestive support. Solgar Probiotics is made available in several varieties designed to provide everyday, bowel, sleep, women's complete, and weight management support.. Key drivers for this market are: Increasing Obesity Concerns Across the Region, Rising popularity of Natural and Organic Ingredients in Weight Management Supplement Products. Potential restraints include: Increasing Obesity Concerns Across the Region, Rising popularity of Natural and Organic Ingredients in Weight Management Supplement Products. Notable trends are: Rising Obesity Concerns Across the Region.

This statistic displays the obesity prevalence in selected European countries by 2025. Great Britain is set to be the most obese nation in Europe by 2025 with an obesity prevalence of 37.7 percent, followed closely by Ireland and Lithuania with an expected prevalence rate of 37.65 percent respectively.

The Europe Weight Management Supplement Market size was valued at USD 129.2 Million in 2023 and is projected to reach USD 212.3 Million by 2032, exhibiting a CAGR of 7.68 % during the forecasts periods. Weight management supplements are products designed to assist individuals in achieving and maintaining a healthy weight. These supplements come in various forms, including capsules, tablets, powders, and liquids, and typically contain a combination of active ingredients such as vitamins, minerals, fiber, herbs, and other bioactive compounds. The primary goal of these supplements is to support weight loss or weight maintenance by enhancing metabolic processes, reducing appetite, and improving fat absorption and utilization. One of the key mechanisms by which weight management supplements work is by boosting metabolism. Ingredients like caffeine, green tea extract, and capsaicin are known to increase metabolic rate, helping the body burn more calories even at rest. This thermogenic effect can contribute to a higher overall calorie expenditure, which is crucial for weight loss. Weight management supplements can support weight loss and maintenance by boosting metabolism, reducing appetite, and improving fat utilization. However, they should be used in conjunction with a healthy diet and exercise regimen for the best results Recent developments include: June 2023: Rapid Nutrition PLC announced the release of its new look and brand identity for the SystemLS weight loss products. The company also claims that it unveiled the new brand identity for the flagship SystemLS Weight Loss Brand as the product continues international expansion., April 2023: Nexira announced the launch of its holistic approach to weight management and introduced two new products, which include products for microbiome modulation called VinOgrape Plus and for appetite control, namely Carolean., March 2023: Novo Nordisk's announced its plans to launch its popular weight loss drug Wegovy in the United Kingdom. The company claims that the UK Medicines and Health Products Regulations Agency approved Wegovy in September 2021 to treat people with a BMI as low as 27., February 2023: Nestlé announced its plans to introduce and sample brand-new product offerings at the Natural Products Expo West 2023 Trade Show. The brand-new offerings include NEW Solgar Probiotic Line. The company claims that Solgar is designed to meet consumers' needs with benefits beyond digestive support. Solgar Probiotics is made available in several varieties designed to provide everyday, bowel, sleep, women's complete, and weight management support.. Key drivers for this market are: Increasing Obesity Concerns Across the Region, Rising popularity of Natural and Organic Ingredients in Weight Management Supplement Products. Potential restraints include: The High Cost of Weight Loss Products. Notable trends are: Rising Obesity Concerns Across the Region.

Snapshot img

Anorexiants Market Size 2024-2028

The anorexiants market size is forecast to increase by USD 1.02 billion at a CAGR of 4.5% between 2023 and 2028. The market is witnessing significant growth due to the increasing prevalence of obesity, type 2 diabetes, and the approval of new therapeutics for weight loss. The market is segmented into three main categories: online pharmacy, retail pharmacy, and hospital pharmacy. The growing trend of online pharmacy sales is contributing to the market's expansion, as consumers seek convenience and affordability. Catecholamine anorexiants, such as phentermine and diethylpropion, remain popular choices for weight loss. However, the safety and tolerability profiles of these drugs limit their widespread use, particularly among vulnerable populations like children and adolescents, the geriatric population, and those with health and wellness concerns, such as type 2 diabetes. New drugs, such as those targeting neuropeptides and melanocortin receptors, are under development to address these concerns.

Additionally, there is a growing focus on the use of anorexiants for the treatment of specific conditions, such as Attention Deficit Hyperactivity Disorder (ADHD) and neurological disorders like Dravet Syndrome and Lennox Gastaut Syndrome. These indications offer significant growth opportunities for market players, as they expand the addressable patient population.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

Anorexiants, also known as appetite suppressants, are pharmaceutical compounds used to reduce hunger and increase satiety. The prevalence of sedentary lifestyles, physical inactivity, and unhealthy dietary habits have led to a significant increase in the number of individuals suffering from obesity and related health conditions such as cardiovascular diseases, diabetes, and hypertension. According to the World Health Organization, over 1.9 billion adults were overweight or obese in 2016. Anorexiants play a crucial role in managing weight loss for individuals diagnosed with various conditions, including obesity, ADHD, Dravet syndrome, and Lennox-Gastaut syndrome.

In addition, these conditions can lead to excessive weight gain and complicate the management of underlying health issues. Anorexiants can be administered orally or subcutaneously in the form of tablets, capsules, or subcutaneous injections. The market for anorexiants is driven by several factors. The rising prevalence of obesity and obesity-related health conditions is a significant factor. Additionally, the increasing awareness of the health risks associated with obesity and the availability of various treatment options are expected to fuel market growth. Furthermore, the growing number of hospitals, specialty clinics, and homecare services offering weight loss programs is expected to create new opportunities for anorexiants.

Furthermore, catecholamines anorexiants and serotonin anorexiants are the two primary types of anorexiants. Catecholamines anorexiants, also known as sympathomimetic anorexiants, work by stimulating the sympathetic nervous system, which leads to an increase in heart rate, blood pressure, and metabolism. Serotonin anorexiants, on the other hand, work by increasing the levels of serotonin in the brain, which helps regulate appetite. The use of anorexiants is not without risks, and their long-term use can lead to various side effects, including cardiovascular problems, high blood pressure, and psychiatric disorders. Therefore, it is essential to monitor patients closely while using anorexiants and follow the prescribed dosage carefully.

In conclusion, the market is expected to grow significantly due to the increasing prevalence of obesity and related health conditions, growing awareness of weight management, and the availability of various treatment options. The market is segmented into catecholamines anorexiants and serotonin anorexiants, with each segment offering unique benefits and challenges. It is crucial to ensure proper patient monitoring and adherence to prescribed dosages to minimize potential risks.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Distribution Channel

  Hospital pharmacy
  Retail pharmacy
  Online pharmacy


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    Japan


  Rest of World (ROW)

By Distribution Channel Insights

The hospital pharmacy segment is estimated to witness significant growth during the forecast period. In the pharmaceutical industry, hospital pharmacies play a crucial role in dispensing medications developed by pharmaceutical companies. These companies conduct extensive research and dev

Snapshot img

Weight Management Devices Market Size 2024-2028

The weight management devices market size is projected to increase by USD 5.21 billion, at a CAGR of 6.78% between 2023 and 2028.

Rising Obesity Rates: The increasing prevalence of obesity is driving demand for effective weight management solutions.
Growing Awareness: Increased awareness about the benefits of weight management and the role of lifestyle diseases is fueling acceptance of advanced weight management devices.
Market Focus: The market emphasizes devices that help with weight control and prevention of lifestyle-related diseases, which are growing health concerns globally.



Obesity Crisis: The rising obesity rate globally is a key factor driving demand for weight management devices.
Health Consciousness: A greater focus on health and weight management, combined with the increasing recognition of the benefits of dietary supplements, is accelerating the adoption of these devices.
Impact on Global Health: Weight management devices play an important role in combating lifestyle diseases, which further contributes to their growing market acceptance and expansion.

What will be the Size of the Weight Management Devices Market during the Forecast Period?

To learn more about the market report, Download Free Sample

Weight Management Devices Market Segmentation

The weight management devices market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in 'USD Billion' for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

Type Outlook

  Fitness equipment
  Surgical equipment





Distribution Channel Outlook 

  Offline
  Online





Region Outlook 

  North America

    The U.S.
    Canada





  Europe

    The U.K.
    Germany
    France
    Rest of Europe





  APAC

    China
    India





  Middle East & Africa

    Saudi Arabia
    South Africa
    Rest of the Middle East & Africa


  South America

    Chile
    Argentina
    Brazil

By Type

The market share growth by the fitness equipment segment will be significant during the forecast period. The global weight management devices market encompasses various segments, with protein supplements and fitness equipment holding significant market shares in 2023. Chronic diseases such as diabetes, hypertension, and orthopedic conditions fuel the demand for these devices. Lifestyle diseases, including obesity, overweight, heart disease, and cancer, contribute to the increasing obesity rates, further driving market growth.

Protein supplements provide essential nutrients for muscle growth and recovery, making them popular among fitness enthusiasts and those undergoing weight loss programs. Fitness equipment, including cardiovascular training equipment like elliptical trainers, rowing machines, treadmills, stationary cycles, and stair steppers, as well as strength training equipment, cater to the growing health and wellness trends.

Get a glance at the market contribution of various segments. Download the PDF Sample

The fitness equipment segment was the largest and was valued at USD 6.19 billion in 2018. The service segment, comprising consultation services, fitness training equipment, and physical training centers, offers professional guidance and support to individuals seeking weight management solutions.

The weight management devices market is expanding rapidly, driven by innovative solutions in the weight-loss devices market and weight control products management devices market. According to the weight management devices market research report, advancements in technology are transforming the industry. The weight loss and obesity management devices market continues to grow, offering personalized solutions for effective weight loss management devices.

By Distribution Channel

Based on the product, the market has been segmented into online and offline channels. The market for weight management devices encompasses a range of offerings, including protein supplements, fitness equipment, and services. This sector experiences significant growth due to the increasing prevalence of chronic diseases such as diabetes, hypertension, and orthopedic conditions. Online communities and professional services cater to those battling obesity, which is a major contributor to lifestyle diseases like heart disease and cancer. Obesity rates continue to rise, fueling the demand for functional beverages, functional food, and dietary supplements, digestive health supplements, and weight loss supplements.

Cardiovascular training equipment, strength training equipment, and surgical equipment are essential tools in the fight against weight-related health issues. Health clubs, consultation services, fitness training and physical training centers offer various solutions to help individuals manage their weight and improve overa

The European Health Interview Survey (EHIS) is a major European Union reference source for comparative statistics on health status, health determinants and use of health care services. It was planned that EHIS would be conducted once every five years.

The first wave of EHIS was launched under an informal agreement and implemented in 17 EU Member States and in Switzerland and Turkey between 2006 and 2009. The second wave of EHIS was completed under a European Parliament and Council regulation in all 28 EU Member States, Iceland, Norway and Turkey between 2013 and 2015. The third wave of EHIS took place in 2019 and 2020 and was completed by all member sates in accordance with the European Parliament and Council regulation. The UK was required to complete EHIS Wave 3 as the UK was a member state in 2019. Users should note that the United Kingdom opted out of the first wave and did not take part, so UK EHIS data exists only from Wave 2 and Wave 3. This dataset contains only the UK responses.

Further information about the survey may be found on the European Commission European Health Interview Survey webpage.

Latest edition information
For the second edition (March 2022), data and documentation for Wave 3 were added to the study.

The European weight loss surgery market is experiencing robust growth, driven by rising obesity rates, increasing awareness of bariatric procedures, and advancements in minimally invasive surgical techniques. The market, valued at approximately €X million in 2025 (assuming a logical extrapolation based on the provided CAGR of 15% and the unspecified market size "XX" – a precise figure requires the missing "XX" value), is projected to reach €Y million by 2033. This significant expansion is fueled by several key factors. The increasing prevalence of obesity and related comorbidities like type 2 diabetes and cardiovascular disease is creating a substantial demand for effective weight loss solutions. Furthermore, technological advancements in devices such as suturing devices, stapling devices, and implantable gastric bands are leading to safer, less invasive procedures with improved patient outcomes, driving market penetration. The segment of assisting devices, encompassing suturing, closure, and stapling devices, is expected to dominate the market due to its widespread use in various bariatric surgeries. However, the growth is also influenced by factors like high procedure costs, potential complications associated with surgery, and varying reimbursement policies across European countries. Growth across the major European markets – Germany, the United Kingdom, France, Italy, and Spain – will contribute significantly to the overall market expansion. However, disparities in healthcare infrastructure and insurance coverage may lead to regional variations in adoption rates. The competitive landscape includes established players like Allergan, Ethicon, and Covidien, as well as emerging companies focusing on innovative technologies. These companies are constantly investing in research and development to introduce advanced devices and improve surgical techniques, further propelling the market's growth. While regulatory hurdles and potential risks associated with weight loss surgery present challenges, the overall outlook for the European weight loss surgery market remains positive, indicating substantial growth opportunities over the forecast period. (Note: 'X' and 'Y' represent calculated values derived from the 15% CAGR and the missing base market size. To obtain precise figures, the missing market size data is required). Recent developments include: In June 2022, Rhythm Pharmaceuticals, Inc. announced that IMCIVREE is available to patients in Germany.The European Commission granted IMCIVREE marketing authorization for the treatment of obesity and the management of hunger in adults and children aged 6 and older with genetically confirmed loss-of-function biallelic pro-opiomelanocortin, including proprotein convertase subtilisin/kexin type 1 deficiency or biallelic leptin receptor deficiency., In June 2022, European Medicines Agency (EMA) safety committee Pharmacovigilance Risk Assessment Committee (PRAC) has recommended the withdrawal of European Union (EU) marketing authorisations for amfepramone obesity medicines.. Key drivers for this market are: Increase in Obese Population, Prevalence of Diabetes and Heart Diseases; Government Initiatives to Curb Obesity; Insurance Coverage of Surgeries. Potential restraints include: Increase in Obese Population, Prevalence of Diabetes and Heart Diseases; Government Initiatives to Curb Obesity; Insurance Coverage of Surgeries. Notable trends are: Gastric Balloons Segment is Expected to Witness the Highest CAGR in the Market Over the Forecast Period.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Summary-level data as presented in: "Meta-analysis of genome-wide association studies for body fat distribution in 694,649 individuals of European ancestry." Pulit, SL et al. bioRxiv, 2018. https://www.biorxiv.org/content/early/2018/04/18/304030 **If you use these data, please cite the above preprint. If you have any questions or comments regarding these files, please contact me: Sara L Pulit spulit@well.ox.ac.uk or s.l.pulit@umcutrecht.nl ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ (1) Data files i. whradjbmi.giant-ukbb.meta-analysis.combined.23May2018.txt Meta-analysis of waist-to-hip ratio adjusted for body mass index (whradjbmi) in UK Biobank and GIANT data. Combined set of samples, max N = 694,649. ii. whradjbmi.giant-ukbb.meta-analysis.females.23May2018.txt Meta-analysis of whradjbmi in UK Biobank and GIANT data. Female samples only, max N = 379,501. iii. whradjbmi.giant-ukbb.meta-analysis.males.23May2018.txt Meta-analysis of whradjbmi in UK Biobank and GIANT data. Male samples only, max N = 315,284. iv. whr.giant-ukbb.meta-analysis.combined.23May2018.txt Meta-analysis of waist-to-hip ratio (whr) in UK Biobank and GIANT data. Combined set of samples, max N = 697,734. v. whr.giant-ukbb.meta-analysis.females.23May2018.txt Meta-analysis of whr in UK Biobank and GIANT data. Female samples only, max N = 381,152. vi. whr.giant-ukbb.meta-analysis.males.23May2018.txt Meta-analysis of whr in UK Biobank and GIANT data. Male samples only, max N = 316,772. vii. bmi.giant-ukbb.meta-analysis.combined.23May2018.txt Meta-analysis of body mass index (bmi) in UK Biobank and GIANT data. Combined set of samples, max N = 806,834. viii. bmi.giant-ukbb.meta-analysis.females.23May2018.txt Meta-analysis of bmi in UK Biobank and GIANT data. Female samples only, max N = 434,794. ix. bmi.giant-ukbb.meta-analysis.males.23May2018.txt Meta-analysis of bmi in UK Biobank and GIANT data. Male samples only, max N = 374,756. (2) Data file format CHR: Chromosome POS: Chromosomal position of the SNP, build hg19 SNP: the dbSNP151 identifier of the SNP, followed by the first allele and second allele of the SNP, delimited with a colon. A small number of SNPs (<9,000) from the GIANT data had no dbSNP151 identifier, and are left as just an rsID. Note that these SNPs are also missing chromosome and position information (not provided in the GIANT data). Tested_Allele: the allele for which all association statistics are reported Other_Allele: the other allele at the SNP Freq_Tested_Allele: frequency of the tested allele BETA: the effect size of the tested allele SE: the standard error of the beta P: the p-value of the SNP, as reported from the inverse variance-weighted fixed effects meta-analysis N: the total sample size for this SNP INFO: the imputation quality (info score) of the SNP, as reported by UK Biobank. A number between 0 and 1 indicating quality of imputation (0, poor quality; 1, high quality or genotyped). Note that the summary-level GIANT data does not report info score, so SNPs appearing only in the GIANT analysis do not have info scores.